Zimmer Biomet Holdings, Inc. (ZBH)

Zimmer Biomet Holdings surprised to the upside with its first?quarter 2026 results, beating earnings expectations and drawing fresh attention to the orthopedic specialist’s outlook in a competitive medical technology market.

Zimmer Biomet reported fresh quarterly results and reaffirmed its outlook, while also increasing its fiscal 2026 share repurchase expectations to as much as $1 billion.

Earlier in May 2026, Zimmer Biomet Holdings announced it would increase its fiscal 2026 share repurchase expectations to as much as US$1.00 billion under a pre-existing US$1.50 billion authorization, alongside upcoming management presentations at a major healthcare conference.

Rising earnings projections for the company are highly promising. Existing ZBH holders may find it prudent to retain their position to enjoy long-term momentum. ZBH carries a Zacks Rank #3 (Hold), while ABT has a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Bu…

ZBH Q1 Deep Dive: Sales Force Changes, Tech Investments, and Margin Expansion Shape Outlook